Leerink Partnrs Has Pessimistic View of MDGL FY2026 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of $1.63 per share for the year, down from their previous forecast of $1.72. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.64) per share.

Several other research firms also recently weighed in on MDGL. HC Wainwright boosted their target price on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. UBS Group raised their target price on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. B. Riley boosted their price target on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. Finally, Oppenheimer dropped their target price on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $351.67.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ MDGL opened at $330.27 on Friday. Madrigal Pharmaceuticals has a fifty-two week low of $168.25 and a fifty-two week high of $368.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The business has a 50-day simple moving average of $314.42 and a two-hundred day simple moving average of $276.65.

Insider Activity

In related news, Director Fred B. Craves sold 3,400 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $350.30, for a total value of $1,191,020.00. Following the transaction, the director now directly owns 14,600 shares of the company’s stock, valued at approximately $5,114,380. This trade represents a 18.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Carole Huntsman sold 347 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $116,328.28. Following the sale, the insider now owns 10,438 shares of the company’s stock, valued at approximately $3,499,235.12. This trade represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,090 shares of company stock worth $3,883,621 over the last 90 days. 22.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth $476,000. Creative Planning grew its stake in Madrigal Pharmaceuticals by 20.0% during the 2nd quarter. Creative Planning now owns 3,212 shares of the biopharmaceutical company’s stock valued at $900,000 after acquiring an additional 535 shares in the last quarter. Truist Financial Corp acquired a new stake in Madrigal Pharmaceuticals in the 2nd quarter valued at about $216,000. Sanctuary Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter worth approximately $294,000. Finally, SG Americas Securities LLC acquired a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $414,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.